Gastroesophageal Reflux

Gastroenterology
19
Pipeline Programs
12
Companies
23
Clinical Trials
2 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
2
1
7
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
4100%
+ 21 programs with unclassified modality

On Market (3)

Approved therapies currently available

U
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)Approved
famotidine
Unknown Company
injection2002
U
PANTOPRAZOLE SODIUMApproved
pantoprazole
Unknown Company
oral2016
U
PEPCID ACApproved
famotidine
Unknown Company
oral1999

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
4 programs
1
PantoprazolePhase 4Small Molecule1 trial
24 hour pH testingN/A1 trial
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of AgeN/A1 trial
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal DiseaseN/A1 trial
Active Trials
NCT00523367Terminated25Est. Oct 2010
NCT01048840Completed100Est. Dec 2014
NCT01167543Completed79Est. Nov 2008
+1 more trials
E
EisaiChina - Liaoning
3 programs
1
1
1
rabeprazole and pantoprazolePhase 4Small Molecule1 trial
Rabeprazole sodium 5 mgPhase 3
Rabeprazole sodiumPhase 1
Active Trials
NCT00237367Completed52Est. Apr 2005
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
esomeprazole 20 mgPhase 41 trial
Active Trials
NCT00472550Completed16Est. Nov 2006
Pfizer
PfizerNEW YORK, NY
6 programs
1
5
Pantoprazole for approximately 9 weeksPhase 31 trial
pantoprazolePhase 3Small Molecule1 trial
pantoprazole for approximately 9 weeks.Phase 31 trial
pantoprazole sodium enteric-coated spheroidPhase 31 trial
pantoprazole sodium enteric-coated spheroid suspensionPhase 31 trial
+1 more programs
Active Trials
NCT00744419Completed24Est. Apr 2012
NCT00195208Completed97Est. Nov 2005
NCT00362609Completed59Est. Dec 2007
+3 more trials
UP
UCB PharmaBelgium - Brussels
1 program
1
LafutidinePhase 31 trial
Active Trials
NCT00229424Completed325Est. Jan 2007
Astellas
AstellasChina - Shenyang
1 program
1
FamotidinePhase 2/31 trial
Active Trials
NCT00141960Completed480
Ironwood Pharmaceuticals
1 program
1
IW-3718Phase 21 trial
Active Trials
NCT02030925CompletedEst. Dec 2014
Catalyst Pharmaceuticals
Catalyst PharmaceuticalsCORAL GABLES, FL
1 program
1
MHS-1031Phase 21 trial
Active Trials
NCT05556824RecruitingEst. Mar 2026
Phathom Pharmaceuticals
Phathom PharmaceuticalsFLORHAM PARK, NJ
1 program
1
VonoprazanPhase 11 trial
Active Trials
NCT05343364CompletedEst. Jun 2023
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
5 programs
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-SymptomsN/A1 trial
Natural History of Gastroesophageal Reflux (GER) in Children and AdolescentsN/A1 trial
NexiumN/A1 trial
Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in FranceN/A1 trial
Sleep StudiesN/A1 trial
Active Trials
NCT00567021Completed67,130Est. Dec 2005
NCT00181805Completed25Est. Dec 2014
NCT00170001Completed500Est. Aug 2006
+2 more trials
Bayer
BayerLEVERKUSEN, Germany
1 program
HydrotalciteN/A1 trial
Active Trials
NCT07291700Recruiting167Est. Jan 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Eisairabeprazole and pantoprazole
Heidelberg Pharmaesomeprazole 20 mg
TakedaPantoprazole
Pfizerpantoprazole
Pfizerpantoprazole sodium enteric-coated spheroid
Pfizerpantoprazole sodium enteric-coated spheroid suspension
Pfizerpantoprazole for approximately 9 weeks.
PfizerPantoprazole for approximately 9 weeks
UCB PharmaLafutidine
AstellasFamotidine
Catalyst PharmaceuticalsMHS-1031
Ironwood PharmaceuticalsIW-3718
Phathom PharmaceuticalsVonoprazan
Pfizerpantoprazole
BayerHydrotalcite

Showing 15 of 23 trials with date data

Clinical Trials (23)

Total enrollment: 72,355 patients across 23 trials

NCT00237367Eisairabeprazole and pantoprazole

A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn

Est. completion: Apr 200552 patients
Phase 4Completed
NCT00472550Heidelberg Pharmaesomeprazole 20 mg

Esomeprazole and Gastric Emptying of Beer

Start: Jan 2006Est. completion: Nov 200616 patients
Phase 4Completed
NCT00246909TakedaPantoprazole

Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)

Start: Nov 2005Est. completion: Nov 2006600 patients
Phase 4Completed
NCT00362609Pfizerpantoprazole

Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD

Start: Jul 2006Est. completion: Dec 200759 patients
Phase 3Completed
NCT00300755Pfizerpantoprazole sodium enteric-coated spheroid

Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)

Start: May 2006Est. completion: Apr 200860 patients
Phase 3Completed
NCT00259012Pfizerpantoprazole sodium enteric-coated spheroid suspension

Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD

Start: Nov 2005Est. completion: Mar 200867 patients
Phase 3Completed
NCT00141817Pfizerpantoprazole for approximately 9 weeks.

Study Evaluating Pantoprazole in Children With GERD

Start: Aug 2005Est. completion: Nov 200741 patients
Phase 3Completed
NCT00195208PfizerPantoprazole for approximately 9 weeks

Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis

Start: Jun 2005Est. completion: Nov 200597 patients
Phase 3Completed
NCT00229424UCB PharmaLafutidine

Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -

Start: Apr 2005Est. completion: Jan 2007325 patients
Phase 3Completed
NCT00141960AstellasFamotidine

Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease

Start: Sep 2005480 patients
Phase 2/3Completed
NCT05556824Catalyst PharmaceuticalsMHS-1031

Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

Start: Mar 2023Est. completion: Mar 2026
Phase 2Recruiting
NCT02030925Ironwood PharmaceuticalsIW-3718

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

Start: Feb 2014Est. completion: Dec 2014
Phase 2Completed
NCT05343364Phathom PharmaceuticalsVonoprazan

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease

Start: May 2022Est. completion: Jun 2023
Phase 1Completed
NCT00744419Pfizerpantoprazole

Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants

Start: May 2009Est. completion: Apr 201224 patients
Phase 1Completed
NCT07291700BayerHydrotalcite

Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy

Start: Nov 2025Est. completion: Jan 2026167 patients
N/ARecruiting
NCT00681837AstraZenecaPrevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France

Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France

Start: May 2008Est. completion: Sep 20082,500 patients
N/ACompleted
NCT00523367Takeda24 hour pH testing

COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI

Start: Aug 2007Est. completion: Oct 201025 patients
N/ATerminated
NCT00462137AstraZenecaSleep Studies

The Influence of Hypnotic Medications on Sleep Arousal and Its Effect on Gastroesophageal Reflux

Start: Mar 2006Est. completion: Mar 20088 patients
N/ACompleted
NCT00567021AstraZenecaGerman PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms

German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms

Start: Sep 2005Est. completion: Dec 200567,130 patients
N/ACompleted
NCT01167543TakedaRelationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease

Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease

Start: Sep 2005Est. completion: Nov 200879 patients
N/ACompleted
NCT00170001AstraZenecaNexium

Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy

Start: Apr 2005Est. completion: Aug 2006500 patients
N/ACompleted
NCT01048840TakedaNatural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age

Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age

Start: Sep 2004Est. completion: Dec 2014100 patients
N/ACompleted
NCT00181805AstraZenecaNatural History of Gastroesophageal Reflux (GER) in Children and Adolescents

Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents

Start: Sep 2004Est. completion: Dec 201425 patients
N/ACompleted

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
7h ago

Key Account Director, Diagnostics and Research

Tempus
Remote
20h ago
$150K - $200K/yr

Experienced Clin Programmer

Johnson & Johnson
High Wycombe, Buckinghamshire, United Kingdom
20h ago

[Innovative Medicine] Director, Government Affairs and Policy Dept., Integrated Market Access Div.

Johnson & Johnson
Chiyoda, Tokyo, Japan
20h ago

Analyst Accounting

Johnson & Johnson
Suzhou, Jiangsu, China
20h ago

Lead Product Security Engineer

Johnson & Johnson
Danvers, Massachusetts, United States of America
20h ago
$94K - $152K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 72,355 patients
12 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)Gastrointestinal Tolerance(12)